SC
HRTX icon

Searle & Co’s Heron Therapeutics HRTX Stock Holding History

Searle & Co’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69K Hold
86,250
– – 0.02% 192
2025
Q4 		$112K Hold
86,250
– – 0.03% 185
2025
Q3 		$109K Hold
86,250
– – 0.03% 183
2025
Q2 		$179K Hold
86,250
– – 0.05% 179
2025
Q1 		$190K Hold
86,250
– – 0.05% 172
2024
Q4 		$132K Hold
86,250
– – 0.04% 174
2024
Q3 		$172K Buy
86,250
+75,250
+684% +$180K 0.04% 166
2024
Q2 		$38.5K Sell
11,000
-75,250
-87% -$231K 0.01% 181
2024
Q1 		$239K Buy
86,250
+1,000
+1% +$2.51K 0.06% 149
2023
Q4 		$145K Hold
85,250
– – 0.04% 155
2023
Q3 		$87.8K Buy
85,250
+7,000
+9% +$9.96K 0.03% 141
2023
Q2 		$130K Buy
78,250
+15,000
+24% +$26.8K 0.04% 149
2023
Q1 		$151K Buy
63,250
+30,000
+90% +$75.1K 0.05% 143
2022
Q4 		$83.1K Hold
33,250
– – 0.03% 146
2022
Q3 		$140K Hold
33,250
– – 0.05% 139
2022
Q2 		$93K Hold
33,250
– – 0.04% 146
2022
Q1 		$190K Sell
33,250
-14,500
-30% -$106K 0.07% 150
2021
Q4 		$436K Hold
47,750
– – 0.16% 106
2021
Q3 		$510K Buy
47,750
+500
+1% +$6.09K 0.21% 89
2021
Q2 		$733K Buy
47,250
+10,000
+27% +$159K 0.3% 75
2021
Q1 		$604K Sell
37,250
-500
-1% -$8.91K 0.27% 81
2020
Q4 		$799K Sell
37,750
-750
-2% -$13K 0.38% 67
2020
Q3 		$571K Buy
38,500
+9,500
+33% +$148K 0.31% 75
2020
Q2 		$427K Sell
29,000
-500
-2% -$8.21K 0.25% 82
2020
Q1 		$346K Buy
29,500
+17,000
+136% +$320K 0.25% 82
2019
Q4 		$294K Buy
12,500
+1,500
+14% +$33.2K 0.16% 107
2019
Q3 		$204K Sell
11,000
-10,150
-48% -$187K 0.12% 128
2019
Q2 		$393K Buy
+21,150
New +$422K 0.24% 92
2017
Q3 		– Sell
-26,500
Closed -$367K – 129
2017
Q2 		$367K Buy
26,500
+3,000
+13% +$43.5K 0.25% 92
2017
Q1 		$353K Buy
+23,500
New +$325K 0.25% 96

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Searle & Co's HRTX Position: Q1 2026 in Review

Searle & Co held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 86,250 shares worth $69K. The position accounts for 0.02% of the portfolio, ranked #192.

Searle & Co first reported a position in HRTX in Q1 2017 and has held it in 30 quarters since. The position peaked at $799K in Q4 2020. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Searle & Co held 86,250 shares of Heron Therapeutics worth $69K as of Q1 2026.
  • Searle & Co left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up 0.02% of Searle & Co's portfolio in Q1 2026, its #192 holding.
  • Searle & Co first reported a position in Heron Therapeutics in Q1 2017 and has held it in 30 quarters since.
  • Searle & Co's Heron Therapeutics position peaked at $799K in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Searle & Co's 13F filing for Q1 2026, filed 8 May 2026.